rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Francis Cano

Director

Company insider

Files Form 4 as: Director, Dynavax Technologies; Director, Biomerica.

Every Form 4 they filed

In numbers

Trades disclosed
99
Buys
9
Sells
3
Bought
$209K
Sold
$322K
Companies
2
Companies where not an officer
2
First trade
31 May 2006
Last trade
10 Feb 2026
Last filed
10 Feb 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
Dynavax TechnologiesDirector · Biotechnology · last 10 Feb 20262 buys · 3 sells
BMRA BiomericaDirector · Diagnostics & Labs · last 10 Dec 20207 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
10 Feb 2026filed 10 Feb 2026Dynavax TechnologiesBiotechnologySEC FORM 4 Code D—42,663filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivative · BiotechnologySEC FORM 4 Code D—25,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivative · BiotechnologySEC FORM 4 Code D—25,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivativeSEC FORM 4 Code D—25,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivativeSEC FORM 4 Code D—25,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivativeSEC FORM 4 Code D—22,500filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivativeSEC FORM 4 Code D—22,500filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivativeSEC FORM 4 Code D—22,500filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivativeSEC FORM 4 Code D—28,500filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivative · BiotechnologySEC FORM 4 Code D—22,500filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivative · BiotechnologySEC FORM 4 Code D—22,500filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivative · BiotechnologySEC FORM 4 Code D—22,500filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivative · BiotechnologySEC FORM 4 Code D—28,500filing
10 Feb 2026filed 10 Feb 2026Dynavax TechnologiesSEC FORM 4 Code D—42,663filing
11 Jun 2025filed 13 Jun 2025Dynavax Technologiesoption or derivativeSEC FORM 4 Code A—28,500 at $0.00filing
11 Jun 2025filed 13 Jun 2025Dynavax TechnologiesSEC FORM 4 Code A—5,758 at $0.00filing
31 May 2024filed 3 Jun 2024Dynavax TechnologiesSEC FORM 4 Sold$43K3,615 at $11.93filing
24 May 2024filed 28 May 2024Dynavax Technologiesoption or derivativeSEC FORM 4 Code M—7,500 at $0.00filing
24 May 2024filed 28 May 2024Dynavax TechnologiesSEC FORM 4 Code M$44K7,500 at $5.90filing
24 May 2024filed 28 May 2024Dynavax TechnologiesSEC FORM 4 Code F$44K3,885 at $11.39filing

Sectors

Health Care7
Not placed5

Buys in green, sells in red, by the company’s sector.

Related people

Deep Track Biotechnology Master Fund, Ltd.10% owner · 10% owner at Dynavax Technologies, filing Form 4 there in the last year
Scott Dunseth MyersDirector · Director at Dynavax Technologies, filing Form 4 there in the last year
John L. SlebirSVP General Counsel · SVP General Counsel at Dynavax Technologies, filing Form 4 there in the last year
David F. NovackPresident & COO · President & COO at Dynavax Technologies, filing Form 4 there in the last year
Ryan SpencerCEO and Director · CEO and Director at Dynavax Technologies, filing Form 4 there in the last year
Allen BarbieriExecutive Vice Chairman · Also traded BMRA in the last 90 days
David MoatazediDirector and Officer · Also traded BMRA in the last 90 days
Eric ChinDirector · Also traded BMRA in the last 90 days